Molecular Formula | C18H13ClN2O2 |
Molar Mass | 324.76 |
Density | 1.405±0.06 g/cm3(Predicted) |
pKa | 8.26±0.20(Predicted) |
Storage Condition | 2-8°C |
MDL | MFCD00980987 |
In vitro study | CPYPP binds to DOCK2 DHR-2 domain in a reversible manner and inhibited its catalytic activity in vitro. When lymphocytes are treated with CPYPP, both chemokine receptor- and antigen receptor-mediated Rac activation are blocked, resulting in marked reduction of chemotactic response and T cell activation. Although overexpression of DOCK2 induces Rac activation in HEK293T cells, this activation is markedly suppressed by treating the cells with CPYPP at 100 µM for 1 hr before assay. |
In vivo study | When 2.5 mg/kg of CPYPP is administrated intravenously, the plasma concentration of CPYPP is only 2.4 µM at 30 min. However, by intraperitoneally injecting 250 mg/kg of CPYPP into mice, the plasma concentration of CPYPP reached to 11.3 µM at 30 min and 10.9 µM at 1 hr, respectively. The adoptively transferred spleen cells from mice that has been made by a ‘‘knock-in’’ strategy to express endogenous DOCK2 as a fusion protein with green fluorescent protein (GFP). Intraperitoneal injection of CPYPP (5 mg per mouse) 1 hr before adoptive transfer reduces the percentage of the migrated T cells to <25% of the control level. |
biological activity | CPYPP is a DOCK2-Rac1 interacting inhibitor. CPYPP binds to the DOCK2DHR-2 domain and inhibits DOCK2DHR-2 of the guanine nucleotide exchange factor activity against Rac1 in a dose-dependent manner with an IC50 of 22.8 μm. CPYPP also inhibits DOCK180 and DOCK5, with less inhibitory activity against dock9. |
Target | IC50: 22.8 µm (GEF activity of DOCK2 DHR-2 for Rac1) |